About PCAI
PCAI is a Toronto-based pharmaceutical company with an ongoing mission to build a global enterprise with a strong foundation of science, research, development and treatment, as well as new therapeutic formulation discovery using data mining and current state-of-the-art artificial intelligence (“AI”) techniques. PCAI’s research and treatment initiatives are dedicated to unlocking the healing potential of plant-based and fungal-based medicines, remedies and treatments through rigorous science and clinical support.
To accomplish our corporate goals, PCAI recently acquired AI Pharmaceuticals, Ltd. in Jamaica where this type of research is federally legal.
AI Pharma’s pharmaceuticals, nutraceuticals and cosmeceuticals will be developed utilizing specific chemical compounds, identified with our AI techniques, from both medical cannabis and medical mushrooms combined together to significantly increase treatment efficacy. We intend to develop a large intellectual property portfolio comprising significant blocking patents including these combinatorial pharmaceutical treatments.
These pharmaceutical, nutraceutical and cosmeceutical products will be developed leveraging the most healing chemical compounds from medical cannabis in combination with chemical compounds from psychedelic and edible mushrooms with a goal to successfully treat conditions like cancer, depression, PTSD and others, as well as opioid and alcohol addiction.
Ultimately, PCAI is focusing on the next wave of science and therapeutics for this $100B annual total addressable market.
This incredible opportunity to discover and patent protect pharmaceutical formulations combining compounds from these two amazing healing gifts of nature in a fully legal environment provides AI Pharma a great time advantage in creating a large and valuable global intellectual property portfolio of seminal blocking patents backed by basic science and clinical data.
The backbone of AI Pharma’s pharmaceutical formulation discovery is state-of-the-art artificial intelligence techniques with world-renowned AI experts. As noted, we intend to produce a line of therapeutic pharmaceuticals, nutraceuticals, and cosmeceuticals comprising our patented formulations to be sold globally where legally allowed as more and more countries reduce their legal restrictions as has happened with medical cannabis worldwide. We will also provide treatment by our team of Licensed Doctors to international and Jamaican patients at our award-winning treatment facility in Negril, Jamaica.
The PCAI Team
Dr. Stephen Barnhill
Executive Chairman, Medical Director
Dr. Stephen D. Barnhill is a physician, Fellowship trained in Laboratory Medicine and Board Certified by the American Board of BioAnalysis.
Dr. Barnhill has been Founder, Chairman and CEO of both private and public companies. He was most recently Founder, Chairman and CEO of a US publicly-traded international biotech company, which he took from inception to profitability.
In addition, he was Founder, Chairman and CEO of BCL laboratories, LLC with operations in the Southeastern United States, which was acquired by Corning-MetPath now Quest Diagnostics, the largest clinical laboratory in the world.
He was also Founder, Chairman and CEO of National Medical Specialty Labs which was acquired by Horus Therapeutics, Inc., a New York-based pharmaceutical company.
Dr. Barnhill is a pioneer in machine learning and pattern recognition algorithms and an inventor on more than 40 patents including neural networks and support vector machines (SVMs) including the hallmark (SVM-RFE) technique (now cited by more than 10,000 publications). His patents were part of the Intellectual Property portfolio that won the first place MICO Award from MDB Capital, winning over Intellectual Property portfolios from 1600 publicly-traded companies.
Dr. Barnhill’s Neural Network patents were acquired by Johnson & Johnson. He is also an inventor on patents related to laboratory developed tests (LDTs). He has worked in the clinical laboratory in clinical chemistry, hematology, microbiology, blood banking, toxicology and immunology, as well as, diagnostic test development relating to cancers of the prostate, colon, pancreas, breast and ovary, cytogenetics, flow cytometry, FISH and imaging in digital mammography, fundoscopic analysis of macular degeneration (AMD) and launched the first iPhone App using SVMs for melanoma detection.
Dr. Barnhill has negotiated and executed deals with many companies including Pfizer, Corning-MetPath, Quest Diagnostics, Clarient (now GE Healthcare), LabCorp, NeoGenomics, Abbott, Bruker and others. He has published many papers with academics including those from MD Anderson Cancer Center, Johns Hopkins University Medical Center, Stanford University Medical Center and others.
He is a frequently invited speaker to medical conferences in the US and internationally. Additionally, he has raised millions of dollars in start-up and on-going financing for both private and public companies.
Dr. Barnhill is or has been a Fellow of the American College of Physician Inventors, the American College of International Physicians, the American Medical Association, the American College of Physician Executives, the American Association of Artificial Intelligence, the American College of Managed Care Medicine, the Association of Clinical Scientists, the American Society of Contemporary Medicine and Surgery, the American Society of Law, Medicine and Ethics, the Southern Medical Society, the American Federation for Clinical Research, National Federation of Catholic Physicians and the Society of Cannabis Clinicians.
Paul Crath
CEO
Paul Crath has over 25 years of transactional, structuring and advisory experience in all three aspects of business and commercial law: As a lawyer, in-house legal counsel, as well as in senior executive positions with several well-established family offices and private merchant banks.
Mr. Crath’s international experience in both public and private market transactions has had him advise numerous portfolio companies and projects in global markets including the US, Canada, China and Latin America.
He has completed transactions and advised clients in numerous sectors including financial services, industrial companies, industrial manufacturing technology, telecom, real estate, mining, oil and gas. Mr. Crath’s work in these areas has included taking a lead role in the structuring, negotiation and completion of all documentation related to financing and offering documents including private placements, public offerings, bank financings, mergers and acquisitions and divestitures for public and private companies.
In the capital markets area, Mr. Crath has completed and advised as in-house counsel on multiple reverse take over and initial public offering transactions, including change of business and restructurings in US and Canadian markets and has experience in the US/Canadian cross-listing process having managed several OTCQX and OTCQB listings for Canadian companies.
He has extensive experience on all legal matters relating to merchant banking, family offices, and investment partnerships and the investment and management of their portfolio companies, having acted as general counsel and lead internal legal advisor on structuring, restructuring, finance, M&A and numerous governance related matters, including managing litigation and regulatory compliance matters and advising special committees of private and public Boards of Directors.
Mr. Crath began his career as a corporate lawyer at White & Case LLP specializing in banking, finance, structured finance and mergers and acquisitions. He then became an advisor to Canadian family offices on their global investments and was a principal at private equity firms focused on mining and resources, real estate, healthcare, specialty technology in global markets including China and Russia.
He has advised Canadian broker dealers on their Canadian, US and international activities.
Mr. Crath is also a board member and CEO of a number of Canadian public companies that have been restructured and undergone numerous reverse merger transactions.
Troy McIntyre
Founder, Director
Troy McIntyre is a serial entrepreneur with two decades of experience in private equity finance, corporate structure, and real estate development.
Mr. McIntyre is known as a visionary with a proven ability to cultivate strategic business alliances with a local and international footprint.
He has been instrumental in raising pre-public equity and debt investment capital in several private start-ups turned public. He’s responsible for identifying high level, tier-one industry partners and negotiating/structuring B2B and B2C arrangements including governments, partnerships, and joint ventures both domestic and international.
Mr. McIntyre earned a Bachelor of Commerce from the University of British Columbia (UBC) and he currently resides in the greater Vancouver, B.C., Canada, area.
Tyler Burpee
Founder, Director
Tyler Burpee is a capital markets professional with over 20 years of experience.
His most recent experience in the cannabis industry includes the founding of a cannabis merchant bank in 2014 with seed investments in WeedMd, Farmacopeia (now Fleurish) and The Hydropothecary Corp. (now Hexo).
Mr. Burpee was a founding shareholder of Nexien Biopharma Inc. (NXEN) a cannabinoid-focused pharmaceutical development company.
He was also a co-founder of Avalon Bridge Capital.
Mr. Burpee has been a partner at Fallon Capital since 2013.
Prior to that, he served as a consultant at Norvista Resources; was a manager of business development at Highvista Gold; and worked in the corporate development department of Levon Resources.
Mr. Burpee also has a corporate finance background. which began with his employment at Kingsdale Capital and PVB Capital.
He earned a Bachelor’s degree from the University of Western Ontario.
